Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 76Carcinoma, Hepatocellular 47Ovarian Neoplasms 40Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Neoplasm Metastasis 13Breast Neoplasms 13Glioblastoma 12Endometrial Neoplasms 12Brain Neoplasms 12Colonic Neoplasms 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Uterine Cervical Neoplasms 9Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Gastrointestinal Neoplasms 4

Interventions

Injections 2Midazolam 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Malignancies × Bevacizumab × Clear all
NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡